Hi! I'm a microbiologist and I've done work in academia, pharma, and clinical trials.
So the most exciting thing about this article is the last paragraph tbh (working on getting the actual paper, it's not up on sci-hub yet).
The company mentioned, Anokion, has four registered clinical trials for both Celiac and MS patients. The trial for Celiac just submitted data from their phase 1 trial (meaning there's good data it is safe) and are recruiting for a Phase 1/2 trial (meaning they are now testing efficacy). After that, the big hurdle is phase 3, which looks at whether or not it is better than a current treatment. The projected completion date is spring 2025. They are also preparing for a Phase 2 trial but are not yet recruiting.
The phase 1 MS trial is currently active, estimated completion in summer 2024.
I checked the company website and it looks like they are in the process of submitting an investigational new drug (IND) application for Type 1 diabetes. This is the first step to starting clinical safety and efficacy trials.
Now clinical trials can get delayed for a variety of reasons, but this is a really good sign! It's way further along than I initially thought when seeing the news. If the treatment does well, we could see new drugs on the market for Celiacs as early at 2030ish and MS as early as 2035.